Cobenfy is an oral xanomeline-trospium medicine approved for adults with schizophrenia.
Leading American pharmaceutical company specializing in research and development.
Founded in New York City, Bristol-Myers Squibb Company is a leading American pharmaceutical organization dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The company's core mission is to transform patients' lives through science, with a vision to be the world's leading biopharma company. Bristol-Myers Squibb offers a range of biopharmaceutical products targeting hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. Key products include Eliquis for stroke/systemic embolism reduction and Opdivo for various anti-cancer indications.
Notable affiliated individuals include key scientists and executives who have driven the company's research and development efforts. The company has received significant investment from major stakeholders in the pharmaceutical industry. Bristol-Myers Squibb's key achievements include the successful development and commercialization of groundbreaking therapies like Eliquis and Opdivo, which have had a substantial impact on patient care globally. The company continues to be a pivotal player in the biopharmaceutical sector, advancing medical research and improving health outcomes worldwide.
Companies similar to Bristol Myers Squibb include Leal Therapeutics, Eli Lilly and Company, Regeneron Pharmaceuticals and Novartis.
Bristol Myers Squibb was founded in 1887.
Bristol Myers Squibb's headquarters is located in New York City, NY, US.
Bristol Myers Squibb's most recent funding round was for $4.5B (USD) in October 2023.
As of Oct 30, 2023, Bristol Myers Squibb has raised a total of $10.6B (USD).
Bristol Myers Squibb has 34,300 employees as of Feb 6, 2024.
Regeneron Pharmaceuticals
regeneron.com